Financial Guidance and Company Overview
Licensable Auto Injector Platform Can Drive Meaningful
Revenue Opportunities
Current Applications
Branded devices with
off-patent API
XYOSTED
(testosterone enanthate) injection
Branded/unbranded
generic devices
Branded product and product
life cycle management
teva
teva
Generic EpiPen
Generic Imitrex
dorsia
Selatogrel
Potential Future Applications
Multi-billion dollar large and small molecule
opportunity with potential to convert to Auto Injector
Device
·
High and low viscosity
.
Today up to 2.25mL
amag
FARMACEUTICALS
Potential to develop rapid delivery 5mL Auto Injector
on already validated QuickShotTM / BigShot™ platform
Robust opportunity for new product
launches through 2030
Subcutaneous /
intramuscular viscous therapies
XYOSTED®
(testosterone enanthate) injection @
Makena
Technology Platform with Broad Applicability
Halozyme References: Wall Street consensus estimates
10View entire presentation